Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values

Eleftherios P. Paschalis,Sonja Gamsjaeger, Klaus Klaushofer,Elizabeth Shane, Adi Cohen,Jan Stepan, Imre Pavo,Erik F. Eriksen, Kathleen A. Taylor,David W. Dempster

Bone（2022）

引用 4|浏览30

暂无评分

摘要

Postmenopausal osteoporosis (PMOP) therapies are frequently evaluated by bone mineral density (BMD) gains against patients receiving placebo (calcium and vitamin D supplementation, a mild bone turnover-suppressing intervention), which is not equivalent to either healthy or treatment-naive PMOP.

查看译文

关键词

Bone quality,Bone formation,Postmenopausal osteoporosis,Teriparatide,Human iliac crest biopsies,Raman spectroscopy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要